Celcuity Presents Results from Three Studies at the 2018 San Antonio Breast Cancer Symposium Evaluating HER2-Negative Breast Cancer Tumors with Hyperactive and Co-Activated HER ...

MINNEAPOLIS--(BUSINESS WIRE)--Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantl...